OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
Yahoo15 gün önceLH
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support cu
Yahoo17 gün önceLH
Labcorp And NACHC Announce Strategic Alliance To Support Practice Improvement And Advance Community Health Initiatives Across Community Health Center Network
Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH),
Benzinga17 gün önceLH
Labcorp to Host Investor Day on September 10, 2026
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.
Yahoo18 gün önceLH
Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million
Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.
Yahoo22 gün önceLH
Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?
Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...
Yahoo22 gün önceLH
Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?
In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...
Yahoo23 gün önceLH
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
Yahoo25 gün önceLH